SITC Archive Library

SITC 2017 Annual Meeting: Concurrent Session 207: Clinical Trials: Novel Combinations 

11-21-2017 16:01

The Society for Immunotherapy of Cancer (SITC) hosted "Concurrent Session 207: Clinical Trials: Novel Combinations" during the SITC 2017 Annual Meeting on November 11, 2017. Available here are the presentation slides and video from the session.

Program Organizers

  • Chair: Mario Sznol, MD – Yale School of Medicine
  • Charlie Garnett Benson, PhD – Georgia State University
  • Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute

Program Summary

The Society for Immunotherapy of Cancer's (SITC) 32nd Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy.

Intended Audience

The audience included U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, scroll down to view Related Entries and Links.

#ClinicalTrials#PresentationSlides#Video#AnnualMeeting#SITC
#CombinationTherapy#ImmuneCheckpointInhibitors#AlliedHealth
#Clinician#Industry#Researcher#2017#Biomarkers#ColorectalCancer
#GastrointestinalCancers#Melanoma#NonSmallCellLungCancer
#ProstateCancer#RenalCellCarcinoma#AdoptiveCellTherapy
#Atezolizumab#Nivolumab#Vaccines#Pembrolizumab#AdverseEvents

Statistics
0 Favorited
252 Views
18 Files
0 Shares
783 Downloads

 Video
Attachment(s)
pdf file
A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase...   4.58 MB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase Inhibitor, Combined with Nivolumab in Patients with Advanced Melanoma (MEL), Renal Cell Carcinoma (RCC), or Non-Small Cell Lung Cancer (NSCLC); Presenter: Funda Meric-Bernstam, MD – The University of Texas MD Anderson Cancer Center; Date: November 11, 2017
mp4 file
A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase...   166.06 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: A Phase 1/2 Study of CB-839, a First-in-Class Glutaminase Inhibitor, Combined with Nivolumab in Patients with Advanced Melanoma (MEL), Renal Cell Carcinoma (RCC), or Non-Small Cell Lung Cancer (NSCLC); Presenter: Funda Meric-Bernstam, MD – The University of Texas MD Anderson Cancer Center; Date: November 11, 2017
pdf file
ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combi...   3.21 MB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combination with Pembrolizumab (PEMBRO) in Patients with Non-Small Cell Lung Cancer (NSCLC); Presenter: Leena Gandhi, MD, PhD – NYU Langone Medical Center; Date: November 11, 2017
mp4 file
ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combi...   99.77 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: ENCORE-601: Phase 1b/2 Study of Entinostat (ENT) in Combination with Pembrolizumab (PEMBRO) in Patients with Non-Small Cell Lung Cancer (NSCLC); Presenter: Leena Gandhi, MD, PhD – NYU Langone Medical Center; Date: November 11, 2017
pdf file
OX40 T-cell Costimulatory Agonist BMS-986178 Alone or in ...   1.06 MB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: OX40 T-cell Costimulatory Agonist BMS-986178 Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors: Initial Phase 1 Results); Presenter: Anthony J. Olszanski, MD – Fox Chase Cancer Center; Date: November 11, 2017
mp4 file
OX40 T-cell Costimulatory Agonist BMS-986178 Alone or in ...   141.74 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: OX40 T-cell Costimulatory Agonist BMS-986178 Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors: Initial Phase 1 Results); Presenter: Anthony J. Olszanski, MD – Fox Chase Cancer Center; Date: November 11, 2017
pdf file
Early FDG-PET Response Correlates with Dose and Efficacy ...   2.24 MB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab; Presenter: Jose Saro, MD – Roche Innovation Center Zurich; Date: November 11, 2017
mp4 file
Early FDG-PET Response Correlates with Dose and Efficacy ...   125.21 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab; Presenter: Jose Saro, MD – Roche Innovation Center Zurich; Date: November 11, 2017
pdf file
First-in-Human Phase 1 Dose Escalation and Expansion of a...   1.44 MB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors; Presenter: Zev Wainberg, MD – UCLA School of Medicine; Date: November 11, 2017
mp4 file
First-in-Human Phase 1 Dose Escalation and Expansion of a...   185.23 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors; Presenter: Zev Wainberg, MD – UCLA School of Medicine; Date: November 11, 2017
pdf file
TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Inf...   4.30 MB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Infiltrating T Cell Expansion in Distant Lesions in a Phase 1/2 Study of Intratumoral IMO-2125+ipilimumab in Anti-PD1 Refractory Melanoma Patientss; Presenter: Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center; Date: November 11, 2017
mp4 file
TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Inf...   156.98 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: TLR9 Agonist Harnesses Innate Immunity to Drive Tumor-Infiltrating T Cell Expansion in Distant Lesions in a Phase 1/2 Study of Intratumoral IMO-2125+ipilimumab in Anti-PD1 Refractory Melanoma Patientss; Presenter: Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center; Date: November 11, 2017
pdf file
Pivot-02: Preliminary Safety, Efficacy and Biomarker Resu...   3.91 MB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Pivot-02: Preliminary Safety, Efficacy and Biomarker Results from the Phase 1/2 Study of CD-122-Biased Agonist NKTR-214 Plus Nivolumab in Patients with Locally Advanced/Metastatic Solid Tumors; Presenter: Adi Diab, MD – The University of Texas MD Anderson Cancer Center; Date: November 11, 2017
mp4 file
Pivot-02: Preliminary Safety, Efficacy and Biomarker Resu...   147.60 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Pivot-02: Preliminary Safety, Efficacy and Biomarker Results from the Phase 1/2 Study of CD-122-Biased Agonist NKTR-214 Plus Nivolumab in Patients with Locally Advanced/Metastatic Solid Tumors; Presenter: Adi Diab, MD – The University of Texas MD Anderson Cancer Center; Date: November 11, 2017
pdf file
DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Respons...   5.50 MB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC); Presenter: Douglas McNeel, MD, PhD – University of Wisconsin; Date: November 11, 2017
mp4 file
DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Respons...   147.00 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC); Presenter: Douglas McNeel, MD, PhD – University of Wisconsin; Date: November 11, 2017
pdf file
Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibit...   884 KB   1 version
Uploaded - 11-21-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation; Presenter: Jason Luke, MD – University of Chicago Medical Center; Date: November 11, 2017
mp4 file
Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibit...   126.61 MB   1 version
Uploaded - 12-05-2017
Meeting: SITC 32 Annual Meeting; Concurrent Session 207: Clinical Trials: Novel Combinations; Presentation: Clinical Activity of Adenosine 2A Receptor (A2AR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation; Presenter: Jason Luke, MD – University of Chicago Medical Center; Date: November 11, 2017